Holen Sie sich die Stockscreener-App
56.12
1.15%
0.64
Handel nachbörslich:
56.12
Schlusskurs vom Vortag:
$55.48
Offen:
$55.59
24-Stunden-Volumen:
1.11M
Relative Volume:
2.48
Marktkapitalisierung:
$3.45B
Einnahmen:
$112.53M
Nettoeinkommen (Verlust:
$-258.91M
KGV:
-17.11
EPS:
-3.28
Netto-Cashflow:
$-124.42M
1W Leistung:
+1.59%
1M Leistung:
-5.46%
6M Leistung:
+37.95%
1J Leistung:
+25.13%
1-Tages-Spanne:
$55.47
$58.16
1-Wochen-Bereich:
$53.39
$58.16
52-Wochen-Spanne:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
56.12 | 3.45B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Franklin Resources Inc. Has $13.03 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Barclays PLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children - MarketWatch
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential - Benzinga
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® - GlobeNewswire
Rhythm Pharma's IMCIVREE Wins FDA Approval for Rare Obesity Treatment in Young Children - StockTitan
Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals - Benzinga
Oppenheimer Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - Nasdaq
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Wellington Management Group LLP - MarketBeat
(RYTM) Trading Signals - Stock Traders Daily
State Street Corp Trims Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Fmr LLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
BNP Paribas Financial Markets Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Frazier Life Sciences Management L.P. Acquires 45,648 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
National Bank of Canada FI Has $17.89 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 11,058 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals: A Key Year Ahead (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities - Yahoo Finance
(RYTM) Technical Data - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Goldman Sachs raises Rhythm Pharmaceuticals stock target by 12%, maintains Buy rating - Investing.com Canada
HighVista Strategies LLC Buys 23,064 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Defici - GlobeNewswire
Rhythm Pharma's IMCIVREE Gets UK Approval for Rare Obesity in Children as Young as 2 | RYTM Stock News - StockTitan
12,386 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Intech Investment Management LLC - MarketBeat
Alkeon Capital Management LLC Buys 167,700 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Victory Capital Management Inc. Has $953,000 Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Algert Global LLC - MarketBeat
25,063 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Penserra Capital Management LLC - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Loomis Sayles & Co. L P Invests $33.35 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Where are the Opportunities in (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals retains stock target, buy rating on new data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' (RYTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts - Benzinga
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Principal Financial Group Inc. Increases Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals Provides Information to the Shareholders - Marketscreener.com
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Primecap Management Co. CA - MarketBeat
First Week of RYTM July 2025 Options Trading - Nasdaq
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide - GlobeNewswire
Rhythm Pharma: New Drug Shows 9.6% Weight Loss in Pediatric Obesity Treatment Study | RYTM Stock News - StockTitan
Perceptive Advisors LLC's Strategic Acquisition in Rhythm Pharma - GuruFocus.com
(RYTM) Proactive Strategies - Stock Traders Daily
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - The Manila Times
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock - Investing.com
Rhythm Pharmaceuticals EVP sells $4.43m in stock By Investing.com - Investing.com Nigeria
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rhythm Pharmaceuticals Inc-Aktie (RYTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lee Jennifer Kayden | EVP, Head of North America |
Nov 11 '24 |
Sale |
66.33 |
66,861 |
4,434,882 |
972 |
| Shulman Joseph | Chief Technical Officer |
Nov 11 '24 |
Option Exercise |
12.63 |
13,281 |
167,760 |
13,281 |
| Shulman Joseph | Chief Technical Officer |
Nov 11 '24 |
Sale |
66.44 |
13,281 |
882,341 |
0 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):